BeOne Medicines (BEIGF) Non-Current Deferred Tax Liability (2016 - 2026)

BeOne Medicines (BEIGF) has reported Non-Current Deferred Tax Liability for 11 consecutive years, with $57.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 30.15% year-over-year to $57.4 million in Q2 2026; TTM through Jun 2026 was $57.4 million, a 30.15% increase from a year earlier, with the FY2025 full-year figure at $53.2 million, up 15.14% from the prior year.
• Non-Current Deferred Tax Liability was $57.4 million for Q2 2026 at BeOne Medicines, up from $55.9 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $57.4 million in Q2 2026 and troughed at $14.2 million in Q1 2022.
• A 5-year average of $29.6 million and a median of $18.3 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability decreased 18.18% in 2023 and jumped 195.36% in 2025, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $24.6 million in 2022, then slipped by 18.18% to $20.1 million in 2023, then soared by 129.81% to $46.2 million in 2024, then rose by 15.14% to $53.2 million in 2025, then rose by 7.85% to $57.4 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $57.4 million (Q2 2026), $55.9 million (Q1 2026), and $53.2 million (Q4 2025), per Business Quant data.